肾癌靶向治疗_省肿瘤大会吴晓安.pptVIP

FDA批准用于mRCC的药物 Sunitinib 较IFN-α 显著改善患者生活质量 * CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. ? The main result for this trial was a survival advantage for patients randomized to everolimus: a median progression-free survival time of 4 months compared with 2 months for patients randomized to placebo. HR, hazard ratio; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center. ? This forest plot shows a subset analysis for various subsets in this particular trial. It shows no meaningful difference across subsets whether looking at MSKCC risk, type of previous treatment, age, sex, or geographic region. * IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nephrectomy or no nephrectomy followed by interferon?alfa for all patients. The median overall survival in patients who underwent upfront nephrectomy was nearly 6 months longer (P = .001). These data (which are from trials that accrued in the 1990s) resulted in debulking nephrectomy becoming a standard of care for patients who presented with metastatic kidney cancer. * * CI, confidence interval; mRCC, metastatic renal cell carcinoma; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease. ? Other single?arm phase?II trials in the setting of refractory RCC are evaluating these novel agents. This multicenter, single?arm, phase?II trial examined sunitinib in patients who had received previous bevacizumab?based treatment. A partial response rate of 23% was noted, with approximately 75% of patients experiencing some form of tumor burden reduction. Compared with sunitinib in untreated patients, the objective response rate is approximately one half, but the number of patients with reduced tum